Geode Capital Management
ASBP

Geode Capital Management’s Aspire Biopharma ASBP Stock Holding History

Geode Capital Management’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.9K Buy
10,474
+9,028
+624% +$92K ﹤0.01% 4223
2026
Q1 		$44.7K Buy
1,446
+1,240
+602% +$66K ﹤0.01% 4342
2025
Q4 		$32.7K Sell
206
-2
-1% -$500 ﹤0.01% 4313
2025
Q3 		$51.5K Buy
+208
New +$104K ﹤0.01% 4288

Other funds holding ASBP

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.73B AUM 42.12% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management's ASBP Position: Q2 2026 in Review

Geode Capital Management increased its Aspire Biopharma (ASBP) stake by 624% in Q2 2026, buying an estimated $92K and bringing the position to 10,474 shares worth $55.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4223.

Geode Capital Management first reported a position in ASBP in Q3 2025 and has held it in 4 quarters since. 13 funds tracked by Wall St. Rank hold ASBP as of Q2 2026.

  • Geode Capital Management held 10,474 shares of Aspire Biopharma worth $55.9K as of Q2 2026.
  • Geode Capital Management bought 9,028 Aspire Biopharma shares in Q2 2026, an estimated $92K.
  • Aspire Biopharma made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4223 holding.
  • Geode Capital Management first reported a position in Aspire Biopharma in Q3 2025 and has held it in 4 quarters since.
  • 13 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.